EUCTR2014-001498-15-DKActive, not recruitingPhase 1
OPEN-LABEL PHASE Ib/II, MULTICENTER STUDY OF THE COMBINATION OF RO5479599 WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) OF SQUAMOUS HISTOLOGY WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY OR TARGETED THERAPY FOR NSCLC
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- F. Hoffmann- La Roche Ltd.
- Enrollment
- 17
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- Age >/= 18 years
- •- ECOG performance status (PS) 0 - 1
- •- Histologically confirmed squamous NSCLC patients
- •- Locally advanced or metastatic (stage IIIB or IV) squamous NSCLC
- •- No prior systemic chemotherapy, targeted therapy for metastatic NSCLC
- •- Evidence of at least one radiologically measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- •- Adequate hematological, liver and renal function
- •- Use of highly effective contraception
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 18
Exclusion Criteria
- •- Concurrent therapy with any other investigational drug
- •- History or clinical evidence of central nervous system (CNS) primary tumors or metastases
- •- Evidence of significant, uncontrolled concomitant diseases, which could affect compliance with the protocol or interpretation of results, including uncontrolled diabetes mellitus and/or significant cardiovascular disease or uncontrolled infection
- •- Any other diseases, metabolic dysfunction, a physical examination finding or a clinical laboratory finding, giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug
- •- Major surgery or significant traumatic injury < 28 days prior to the first study treatment infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
- •- Pregnant or breast-feeding women
- •- History of other malignancies that could affect compliance with protocol or interpretation of results. Patients with malignancies diagnosed more than five years prior to study day one, adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer are generally eligible
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A Study Evaluating RO5479599 in Combination with Carboplatin and Paclitaxel in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histologyon-Small Cell Lung CancerMedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001498-15-NLF. Hoffmann- La Roche Ltd.17
Completed
Not Applicable
OPEN-LABEL PHASE Ib/II, MULTICENTER STUDY OF THE COMBINATION OF RO5479599 WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) OF SQUAMOUS HISTOLOGY WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY OR TARGETED THERAPY FOR NSCLCgevorderde en/of gemetastaseerde sqNSCLCsquamous Non-Small Cell Lung Cancer10038666cancerNL-OMON41018Roche Nederland B.V.5
Active, not recruiting
Phase 1
A Study Evaluating RO5479599 in Combination with Carboplatin and Paclitaxel in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histologyon-Small Cell Lung CancerMedDRA version: 17.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001498-15-GBF. Hoffmann- La Roche Ltd.12
Active, not recruiting
Phase 1
A Study Evaluating RO5479599 in Combination with Carboplatin and Paclitaxel in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous HistologyEUCTR2014-001498-15-ESF. Hoffmann- La Roche Ltd.17
Active, not recruiting
Not Applicable
A PHASE Ib/II, OPEN LABEL, MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF Apo2L/TRAIL ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR AND OTHER LOW-GRADE, CD20, B CELL NON HODGKIN?S LYMPHOMAS THAT HAVE PROGRESSED FOLLOWING PREVIOUS RITUXIMAB THERAPY - APO3585gEUCTR2006-005552-33-ITGENENTECH , INC120